UCB (ENXTBR:UCB) - Hisse Senedi Fiyatı, Haberler ve Analizler

UCB Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan UCB SA, dünya çapında nöroloji ve immünoloji hastalıkları olan insanlar için ürünler ve çözümler geliştirmektedir.

Şirket hakkında

UCB temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	1/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 66.9% daha düşük bir oranda işlem görüyor

Kazançların yılda 35.52% oranında artması öngörülüyor

Risk Analizi

Kar marjları (4.4%) geçen yılın (6.5%) altında

UCB SA Rakipler

Financière de Tubize

ENXTBR:TUB

€6.4b

Jiangsu Hengrui Medicine

SHSE:600276

CN¥309.5b

Takeda Pharmaceutical

TSE:4502

JP¥6.8t

Otsuka Holdings

TSE:4578

JP¥5.1t

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti UCB
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€179.45
52 Haftanın En Yüksek Seviyesi	€183.80
52 Haftanın En Düşük Seviyesi	€65.40
Beta	0.36
11 Aylık Değişim	7.84%
3 Aylık Değişim	17.90%
1 Yıllık Değişim	164.21%
33 Yıllık Değişim	71.07%
5 Yıllık Değişim	146.16%
Halka arzdan bu yana değişim	58,709.84%

Son Haberler & Güncellemeler

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

Oct 22

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10

Recent updates

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

Oct 22

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Hissedar Getirileri

	UCB	BE Pharmaceuticals	BE Pazar
7D	-0.1%	-2.8%	-3.2%
1Y	164.2%	10.7%	7.7%

Getiri vs. Endüstri: UCB geçen yıl % 10.7 oranında getiri sağlayan Belgian Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: UCB geçen yıl % 7.7 oranında getiri sağlayan Belgian Piyasasını aştı.

Fiyat Oynaklığı

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement	3.3%
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	3.5%
10% most volatile stocks in BE Market	6.5%
10% least volatile stocks in BE Market	2.3%

İstikrarlı Hisse Senedi Fiyatı: UCB son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: UCB 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1925	9,000	Jean-Christophe Tellier	www.ucb.com

Bir biyofarmasötik şirketi olan UCB SA, dünya çapında nöroloji ve immünoloji hastalıkları olan kişiler için ürünler ve çözümler geliştirmektedir. Şirketin başlıca ürünleri arasında enflamatuar TNF aracılı hastalıklar için Cimzia'nın yanı sıra ankilozan spondilit, aksiyal spondiloartrit, Crohn hastalığı, radyografik olmayan aksiyal spondiloartrit, plak sedef hastalığı, psoriatik artrit ve romatoid artrit yer almaktadır; Epilepsi için Vimpat, Keppra ve Briviact; Parkinson hastalığı ve huzursuz bacak sendromu için Neupro; epilepsi nöbet kümeleri için bir burun spreyi kurtarma tedavisi olan Nayzilam; ve alerjiler için Zyrtec ve Xyzal. Ayrıca menopoz sonrası kadınlarda osteoporoz tedavisi için Evenity; plak sedef hastalığı, psoriatik artrit ve aksiyel spondiloartrit tedavisi için Bimzelx; ve Dravet sendromunu tedavi etmek için Fintepla sunmaktadır.

UCB SA Temel Bilgiler Özeti

UCB'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
UCB temel i̇stati̇sti̇kler
Piyasa değeri	€34.05b
Kazançlar(TTM)	€240.00m
Gelir(TTM)	€5.45b

141.9x

F/K Oranı

6.2x

P/S Oranı

UCB aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
UCB gelir tablosu (TTM)
Gelir	€5.45b
Gelir Maliyeti	€1.76b
Brüt Kâr	€3.70b
Diğer Giderler	€3.46b
Kazançlar	€240.00m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Feb 27, 2025

Hisse başına kazanç (EPS)	1.27
Brüt Marj	67.80%
Net Kâr Marjı	4.40%
Borç/Özkaynak Oranı	31.8%

UCB uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

0.8%

Mevcut Temettü Verimi

108%

Ödeme Oranı

UCB Stoklara Genel Bakış

Ödüller

Risk Analizi

UCB SA Rakipler

ENXTBR:TUB

€6.4b

SHSE:600276

CN¥309.5b

TSE:4502

JP¥6.8t

TSE:4578

JP¥5.1t

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Recent updates

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released